{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:21:10Z","timestamp":1772061670105,"version":"3.50.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"none","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Adamantinomatous craniopharyngiomas (ACPs) are rare, sellar-suprasellar benign tumors that cause considerable morbidity and mortality due to local invasion and treatment-related damage to surrounding structures, including central diabetes insipidus (CDI). Trametinib is a highly selective inhibitor of MEK1 and MEK2, which has been evaluated in both adult and pediatric cancers\/ tumors with activation of the oncogenic mitogen-activated protein kinase (MAPK) pathway. Despite being thought to have fewer side effects than conventional cytotoxic chemotherapy, off-target toxicities such as hyponatremia have been described. The use of MEK inhibitors in ACPs are limited to case reports and a phase II trial is currently underway. We report a pediatric patient with multiply progressive ACP and known brittle CDI who developed severe hyponatremia associated with a significant decrease in desmopressin dosing after starting trametinib and a rapid rebound of desmopressin requirement with its cessation. We recommend close monitoring of serum sodium levels and a review of desmopressin doses in patients with CDI when started on treatment with MEK inhibitors.<\/jats:p>","DOI":"10.1097\/mph.0000000000003116","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T20:00:09Z","timestamp":1757016009000},"page":"e410-e412","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Trametinib-induced Hyponatremia in a Patient With Craniopharyngioma and Diabetes Insipidus"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-1015","authenticated-orcid":false,"given":"Buddhi","family":"Gunasekara","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Great Ormond Street Hospital for Children NHS Foundation Trust"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7161-6297","authenticated-orcid":false,"given":"Harriet","family":"Gunn","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University College London Hospitals NHS Foundation Trust"},{"name":"Genetics and Genomic Medicine Research and Teaching Department, University College London Great Ormond Street Institute of Child Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8909-9948","authenticated-orcid":false,"given":"Arif H.B.","family":"Jalal","sequence":"additional","affiliation":[{"name":"UCL Medical School, University College London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-9807","authenticated-orcid":false,"given":"Darren","family":"Hargrave","sequence":"additional","affiliation":[{"name":"Developmental Biology and Cancer Research and Teaching Department, University College London Great Ormond Street Institute of Child Health"},{"name":"Department of Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-0397","authenticated-orcid":false,"given":"Hoong Wei","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Great Ormond Street Hospital for Children NHS Foundation Trust"},{"name":"Genetics and Genomic Medicine Research and Teaching Department, University College London Great Ormond Street Institute of Child Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"R1-20251028","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2478\/raon-2019-0036","article-title":"Advances in the management of craniopharyngioma in children and adults","volume":"53","author":"Jensterle","year":"2019","journal-title":"Radiol Oncol"},{"key":"R2-20251028","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000515347","article-title":"Postoperative and long-term endocrinologic complications of craniopharyngioma","volume":"93","author":"Bereket","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"R3-20251028","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","article-title":"Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target","volume":"135","author":"Apps","year":"2018","journal-title":"Acta Neuropathol"},{"key":"R4-20251028","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1097\/MPH.0000000000001427","article-title":"Trametinib toxicities in patients with low-grade gliomas and diabetes insipidus: related findings?","volume":"42","author":"Egan","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"R5-20251028","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J Clin Oncol"},{"key":"R6-20251028","doi-asserted-by":"crossref","first-page":"e28753","DOI":"10.1002\/pbc.28753","article-title":"Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma","volume":"68","author":"Patel","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20251028","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s40478-024-01838-4","article-title":"Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression","volume":"12","author":"Apps","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"R8-20251028","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth","year":"2014","journal-title":"Australas J Dermatol"},{"key":"R9-20251028","doi-asserted-by":"crossref","first-page":"15765","DOI":"10.1074\/jbc.M209980200","article-title":"Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity-responsive element in the AQP1 gene","volume":"278","author":"Umenishi","year":"2003","journal-title":"J Biol Chem"},{"key":"R10-20251028","doi-asserted-by":"crossref","first-page":"e550","DOI":"10.1097\/MPH.0000000000001859","article-title":"Trametinib-associated hyponatremia in a child with low-grade glioma is not seen following treatment with alternative MEK inhibitor","volume":"43","author":"Lazow","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"R11-20251028","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N Engl J Med"},{"key":"R12-20251028","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/pcmr.12749","article-title":"Hyponatremia and MAP-kinase inhibitors in malignant melanoma: frequency, pathophysiological aspects and clinical consequences","volume":"32","author":"Assan","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"R13-20251028","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-024-04896-9","article-title":"Endocrine effects of MEK and BRAF inhibitor therapy in paediatric patients: a tertiary centre experience","volume":"172","author":"Jalal","year":"2025","journal-title":"J Neurooncol"},{"key":"R14-20251028","doi-asserted-by":"crossref","first-page":"F240","DOI":"10.1152\/ajprenal.00198.2011","article-title":"Hypotonic stress upregulates \u03b2- and \u03b3-ENaC expression through suppression of ERK by inducing MKP-1","volume":"303","author":"Niisato","year":"2012","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:01:54Z","timestamp":1761652914000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003116","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"2024-06-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}